Atea Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGAtea Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 65), indicating performance broadly in line with the market. Earnings contraction of 43% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.38 | +5.31% | ABOVE |
| 50 SMA | $4.80 | -3.95% | BELOW |
| 100 SMA | $5.03 | -8.27% | BELOW |
| 150 SMA | $4.49 | +2.64% | ABOVE |
| 200 SMA | $4.14 | +11.24% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is AVIR in an uptrend right now?
AVIR has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is AVIR overbought or oversold?
AVIR's RSI (14) is 49. The stock is in neutral territory, neither overbought nor oversold.
Is AVIR outperforming the market?
AVIR has a Relative Strength (RS) Rating of 65 out of 99. AVIR is performing about average compared to the market.
Where is AVIR in its 52-week range?
AVIR is trading at $4.61, which is 72% of its 52-week high ($6.44) and 50% above its 52-week low ($2.78).
How volatile is AVIR?
AVIR has a Beta of 0.72 and 52-week volatility of 49%. It's less volatile than the S&P 500 - generally more stable.